The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
 
Marwan Fakih
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche
Speakers' Bureau - Amgen; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Bert O'Neil
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Genentech/Roche; Merck
Speakers' Bureau - Celgene
Travel, Accommodations, Expenses - Bayer; Merck KGaA
 
Timothy Jay Price
Consulting or Advisory Role - Amgen; Merck Serono (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst)
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BeiGene (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly; Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Precision Oncology (Inst); Regeneron (Inst); Rgenix (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tocagen (Inst); Vegenics (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute
 
Jayesh Desai
Consulting or Advisory Role - Amgen; BeiGene; Bionomics; Eisai; Lilly; Novartis
Research Funding - Bionomics (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)
 
James Kuo
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Zucero Therapeutics
 
Ramaswamy Govindan
Honoraria - Abbvie; Genentech; Janssen; Millennium; Roche
Consulting or Advisory Role - Abbvie; Adaptimmune; AstraZeneca; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; GlaxoSmithKline; Inivata; Lilly; Merck; Nektar; Pfizer; Phillips Gilmore Oncology; Roche
 
Erik Rasmussen
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Phuong Khanh H. Morrow
Employment - Amgen
Leadership - Amgen
Stock and Other Ownership Interests - Amgen
 
Jude Ngang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Haby A. Henary
No Relationships to Disclose
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena; Presagia
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Adaptimmune; Alphasights; Axiom Biotechnologies; Baxter; Bayer; Eisai; Genentech; Gerson Lehrman Group; GroupH; Guidepoint Global; Janssen; Medscape; Merrimack; Numab; Pfizer; Seagen; Takeda; Trieza Therapeutics
Research Funding - Abbvie; Adaptimmune; Amgen; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Fate Therapeutics; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; MOLOGEN; National Cancer Institute; Novartis; Pfizer; Seagen; Takeda
Travel, Accommodations, Expenses - Genmab; Loxo; miRNA Therapeutics